PATENTSCOPE: EN_ALL:nmr AND PA:mylan

POLYMORPHIC FORMS OF BARICITINIB (Fri, 04 Jan 2019)
The present disclosure provides crystalline forms of baricitinib (formula (I)), crystalline forms of solvates of baricitinib and processes for the preparation thereof.
>> Read More

NOVEL POLYMORPHS OF (5-[3-(3-HYDROXYPHENOXY)AZETIDIN-1-YL]-5-METHYL-2,2-DIPHENYLHEXANAMIDE HYDROCHLORIDE (Fri, 21 Sep 2018)
The present disclosure provides solid forms of the hydrochloride salt of (5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide (Compound-A). In particular, an amorphous form, an ethyl acetate solvate form, a methyl n-butyl ketone solvate form, an anisole solvate form, an isobutyl acetate solvate form, a n-butyl acetate solvate form, a toluene solvate form, a 4-methyl-2-pentanol solvate form, a n-propyl acetate solvate form, a xylene solvate form, Form VIII and Form IX of the salt are disclosed. Processes for the preparation of each of the disclosed forms are also provided.
>> Read More

PROCESS FOR THE PREPARATION OF VENETOCLAX (Fri, 16 Feb 2018)
The present disclosure provides novel synthetic process for the preparation of venetoclax. The disclosed processes involve the use of novel intermediates. Processes for the preparation of these intermediates are also disclosed as well as methods for the preparation of particularly useful salts thereof.
>> Read More

PROCESS FOR THE PREPARATION OF SOFOSBUVIR (Fri, 12 May 2017)
A process for the preparation of intermediates 9, useful in the synthesis of sofosbuvir, as well as intermediates of formula [12] are disclosed herein.
>> Read More

PROCESS FOR THE PREPARATION OF VELPATASVIR (Fri, 14 Apr 2017)
The present disclosure provides a process for the preparation of velpatasvir intermediates of formula 5. The intermediates may be further converted to velpatasvir or pharmaceutically acceptable salts thereof.
>> Read More

NOVEL FORMS OF LUMACAFTOR AND PROCESSES FOR THE PREPARATION THEREOF (Fri, 07 Apr 2017)
The present disclosure provides amorphous lumacaftor, amorphous solid dispersions of lumacaftor, crystalline lumacaftor acetic acid solvate, crystalline lumacaftor ethyl acetate solvate, and processes for the preparation thereof. The lumacaftor forms disclosed herein may be useful for the preparation of oral dosage forms for treating cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases.
>> Read More

POLYMORPHS OF IXAZOMIB CITRATE AND PROCESSES FOR THE PREPARATION THEREOF (Fri, 24 Mar 2017)
The present disclosure provides amorphous ixazomib citrate and processes for the preparation thereof. Crystalline form Ml, form M2, form M3, and form M4 of ixazomib citrate are also disclosed. The present disclosure also encompasses processes for the preparation of those crystalline forms.
>> Read More

PROCESS FOR THE PREPARATION OF BREXPIPRAZOLE (Fri, 17 Feb 2017)
The present disclosure provides processes for the preparation of brexpiprazole or pharmaceutically acceptable salts thereof. The present disclosure also provides intermediates useful in the preparation of brexpiprazole.
>> Read More

POLYMORPHIC FORM OF LEDIPASVIR (Fri, 09 Dec 2016)
Novel stable polymorph of ledipasvir designated as form-M1 is disclosed as well as processes for the preparation thereof.
>> Read More

PROCESS FOR THE PREPARATION OF DACLATASVIR (Fri, 11 Nov 2016)
The present disclosure provides a novel process for the preparation of daclatasvir or pharmaceutically acceptable salts thereof using novel intermediates. Formula (I)
>> Read More

CRYSTALLINE FORMS OF IDELALISIB (Fri, 07 Oct 2016)
NOVEL CRYSTALLINE FORMS OF IDELALISIB The preparation of a crystalline form of a idelalisib methyl-tert-butyl ether solvate (form M1) is disclosed herein. Drying of this solvate form M1 at elelvated temparature leads to the idelalisib form M2.
>> Read More

AMORPHOUS APREMILAST, PREMIXES THEREOF, AND NOVEL CRYSTALLINE FORMS OF APREMILAST (Fri, 02 Sep 2016)
A process for the preparation of amorphous apremilast. A premix of amorphous apremilast with pharmaceutically acceptable excipients and process for the preparation thereof are also disclosed. Processes for the preparation of anisole and methyl ethyl ketone solvates of apremilast are disclosed, as are powder X-ray diffraction patterns characterizing those forms of apremilast.
>> Read More

PROCESSES FOR THE PREPARATION OF DOLUTE-GRAVIR (Fri, 12 Aug 2016)
Processes for the preparation of dolutegravir and pharmaceutically acceptable salts utilizing alkenylamine are disclosed. Intermediates in those synthetic schemes are also disclosed.
>> Read More

PROCESS FOR MAKING LOMITAPIDE MESYLATE (Fri, 29 Jan 2016)
The present disclosure provides a process for lomitapide and its pharmaceutically acceptable salts. The present disclosure further provides pharmaceutically acceptable salts (e.g., 5 mesylate) of lomitapide in amorphous form.
>> Read More

PROCESS FOR THE PREPARATION OF EMPAGLIFLOZIN (Fri, 10 Jul 2015)
An improved process for the preparation of empagliflozin is disclosed. Novel intermediates of formulas (13) and (14) for the preparation of empagliflozin are also disclosed, wherein R1 and R2 are independently hydrogen or hydroxyl protecting groups.
>> Read More

PROCESS FOR THE PREPARATION OF SOFOSBUVIR (Fri, 03 Jul 2015)
The present disclosure relates to processes for the preparation of sofosbuvir or of its pharmaceutically acceptable salts. The present disclosure also provides intermediates useful in the synthesis of sofosbuvir.
>> Read More

PROCESS FOR PREPARATION OF ALOGLIPTIN (Fri, 26 Jun 2015)
Processes for the preparation of alogliptin benzoate are disclosed. The present disclosure also provides intermediates useful in the synthesis of alogliptin benzoate.
>> Read More

PREPARATION OF COBICISTAT INTERMEDIATES (Fri, 12 Jun 2015)
The present disclosure provides crystalline piperidine sulfamoyl intermediates of formula 8 and 9. The present disclosure also relates to an improved process for the preparation of cobicistat using compounds of formulae 8 and 9.
>> Read More

PROCESS FOR THE PREPARATION OF COBICISTAT INTERMEDIATES (Fri, 18 Apr 2014)
The present invention relates to cobicistat intermediates, processes and further conversion to cobicistat with improved yield and quality.
>> Read More

SOLID FORM OF ALISKIREN INTERMEDIATE (Fri, 30 Aug 2013)
The present invention relates to isolation of a novel solid form of Aliskiren intermediate of compound of Formula-Y and further conversion into Aliskiren or its pharmaceutically acceptable salts with improved yield and quality.
>> Read More